Tim McGraw weighs in on Diabetes

Did you know 29.1 million people in the U.S. have diabetes?  8.1 million of those may be undiagnosed or unaware of their condition.  According to the American Diabetes Association 33% of those with type 2 diabetes have not reached their target A1C goals.  That means a staggering 7 million people are at a higher risk of many diseases due to high blood glucose, low blood glucose, or swinging between both.

Here at Sestron Clinical Research we provide an opportunity to connect with our doctors, receive diet and exercise counseling, and participate in Clinical Trials for Type 1 and Type 2 diabetes.  You may be wondering why we list participating in a Clinical Trial as a way help someone reach their target A1C goals.

Did you know that most diabetics who participate in a Clinical Trial have a better chance of reaching their target A1C? Research Site’s often have a better ability to provide one-on-one time to get to know you and help you overcome the hurdles you face as an individual with certain lifestyle challenges.  If you live in the Atlanta, GA area we can help. Visit our website http://www.sestron.com.

If you are in the Peach State: Tim McGraw is coming to Atlanta in November for the Kicks Country Fair!

Even if you are not in the Peach State, keep reading!

Why do we care about Tim McGraw (besides the fact that he is a great country artist)?

Merck and the ADA have teamed up with Tim McGraw.  They are running the American’s Diabetes Challenge: “Get to Your Goals” to help people with diabetes work with their doctor to get to their A1C goal.

If you have diabetes, take the challenge. Pledge to work with your doctor to set and reach your own A1C goal. Also, be sure to learn if you are at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk. Friends and caregivers are encouraged to challenge their loved ones to take the pledge and help support the millions of Americans living with this disease.

The American Diabetes Association recommends that people with diabetes have an individualized A1C goal. The goal for many adults with diabetes is less than 7 percent. A higher or lower goal may be appropriate for some people. You should speak with your doctor about what goal is right for you.

Did you know that diabetes disproportionately affects different ethnic groups?

  • 13.2% of all African-American adults live with diabetes
  • 12.8% of all Hispanic adults live with diabetes

“I’ve seen first-hand how type 2 diabetes impacts Americans from all walks of life. It’s affected my family, friends and fans. I’m a strong believer in making healthy choices, so I’m encouraging all Americans to join me and challenge their family and friends with diabetes to work with their doctor to get to their A1C goal. Together, we can make a difference.” – Tim McGraw

Talk to Your Doctor to Know Your A1C

Before your appointment, prepare yourself: Be prepared to talk about how your treatment plan is working for you. Be prepared to set an A1C goal. Your doctor will help set your goal that is right for you. Here are some important questions to address with your doctor.

  • What is my A1C and what should my goal be?
  • What are the signs and symptoms of high and low blood glucose?
  • Do I need to make any changes to my diabetes management plan?
  • What are the benefits and possible side effects of the medicine(s) I’m taking?
  • What are the possible causes of high and low blood glucose?

American Diabetes Association. “American’s Diabetes Challenge.” Diabetes. ADA, 1 Apr. 2015. Web. 15 July 2015.

Accept America’s Diabetes Challenge

CLICK HERE

Do you have questions about Diabetes, Clinical Research, or anything else that we have discussed on our blog?

Leave a comment below!  Other readers and/or our staff may be able to help.

For Diabetes friendly recipes, visit our Facebook Page! CLICK HERE

Advertisements

Diabetes and Alzheimer’s Disease: Could there be a link?

We know that diabetes care has been improving and patients with diabetes are living longer.  In turn, Doctor’s have an older patient population to observe.  Sestron Research recently discovered that leading Doctors around the country have noticed a high percentage of Type 1 and Type 2 diabetics with Alzheimer’s Disease.   Have you ever forgotten where you put your keys? Or wondered if you’ve lost your mind, until you discover your glasses on top of you head? Did you notice a little voice in your head asking “Could this be Alzheimer’s?”.  This is certainly a natural fear, since no one wants to lose their independence.  But if you are a diabetic, or someone you know and love has diabetes, you may want to read this article from Medscape.

Type 1 Diabetes Linked to Increased Dementia Risk

Pauline Anderson

July 23, 2015

WASHINGTON, DC — Older patients with type 1 diabetes (T1D) have more than an 80% increased risk for dementia compared with those without diabetes, a new study suggests.

Previous research showed that older people with type 2 diabetes (T2D) have about a two-fold greater risk for dementia compared with people without diabetes, but the current study is the first to look at dementia risk in elderly adults with T1D.

“There has been a paucity of work in type 1 diabetes because only recently have they been living longer, and living long enough to be at risk for an age-related neurocognitive dysfunction,” Rachel Whitmer, PhD, senior scientist, Division of Research, Kaiser Permanente, Oakland, California, told Medscape Medical News.

Dr Whitmer presented the results here at the Alzheimer’s Association International Conference (AAIC) 2015.

Continue reading

Landmarks in Diabetes: 1995 to 2015

Welcome to the first blog post of Sestron’s Clinical Research News Room.  We are very excited to begin sharing some great resources for information on Clinical Research with you.  We will also share related materials regarding medical advances in the treatment of many diseases we are conducting Clinical Trials on here in Marietta, GA.  The first article I would like to share comes from Medscape.  It covers the some of the greatest game changers in diabetes over the past 20 years.

At Sestron we are conducting clinical trials using the newest medications for the treatment and maintenance of Type 1 and Type 2 Diabetes.  We hope these medications will make the list for “Landmarks in Diabetes” for the 21st century.

Visit our website: www.sestron.com to see what trials are currently available to you for participation.

Read Medscape’s Article below!


Editor’s Note: To commemorate Medscape’s 20th anniversary, they asked several experts to describe how the management of diabetes has evolved over the past 20 years.

The discovery of insulin in 1921 and the availability of home blood glucose monitoring in 1981 perhaps represent the greatest advances thus far in the world of diabetes. But in the past 20 years, numerous incremental developments have also remarkably improved the prognosis and quality of life for patients with both type 1 and type 2 diabetes.

“Twenty years ago, every minute of every day there were patients in my lobby with below-the-knee amputations, seeing-eye dogs, or white canes. Today this is so rare, I am convinced that we are only beginning to understand what the natural history of diabetes will be in the 21st century,” says John Buse, MD, PhD, professor of medicine, dean for clinical research, and chief of the Division of Endocrinology at the University of North Carolina School of Medicine, Chapel Hill. In contrast, he says, “The prognosis for a normal lifespan free of disabling complications, I think, is excellent for people living with diabetes today.”

Of course, progress is often cumulative, and the advances over the past 20 years were built on earlier progress, such as the 1993 landmark Diabetes Control and Complications Trial and the Lower Extremity Amputation Prevention (LEAP) program. The former study found that maintaining blood glucose levels as close to normal as possible slowed the organ damage that often occurs in diabetes. The latter study established the use of the monofilament as an easy, in-office test for foot sensation, notes Charles Clark, MD, professor emeritus of medicine and now associate dean for continuing medical education at the Indiana University School of Medicine.

Looking back over the past 20 years, five particular advances stand out for their role in improving the lives of people with diabetes.

Metformin: The Game Changer

In the United States, 2015 marks the 20-year anniversary of the arrival of the first oral medication for type 2 diabetes that does not cause hypoglycemia. Metformin had been available outside the United States for over a decade, but its approval here was delayed while the US Food and Drug Administration (FDA) focused on removing a related but more toxic compound, phenformin, from the market.

Today, metformin still is used as first-line therapy for type 2 diabetes, owing to its relative efficacy, safety, and low price as a generic.

Add-on glucose-lowering medications offer the advantages of weight loss and improved blood pressure levels. In 2005, the FDA approved the first glucagon-like peptide 1 receptor agonist (exenatide), followed in 2006 by the first dipeptidyl peptidase 4 inhibitor (sitagliptin); the first sodium/glucose cotransporter 2 inhibitor (canagliflozin) arrived in 2013.

For type 2 diabetes, the biggest advance is “the sheer number of effective drugs that have been developed within the past 15 years,” says Cyrus Desouza, MBBS, professor and chief of the Division of Diabetes, Endocrinology and Metabolism at the University of Nebraska Medical Center. “Physicians treating type 2 diabetes have never had so many choices and combinations as now,” he continues. “From a patient’s perspective, this has led to better diabetes control and hence decreased microvascular complications.”

Still, lingering long-term safety questions, the high cost, and the moderate (at best) ability of these agents to lower blood glucose mean that there is plenty of room for further innovation in the years to come.

As Dr. Clark sees it, “Once you had metformin, everything else was incremental. Metformin was the game changer.”

Glucose Monitoring and Insulin Pumps

Continuous glucose monitoring (CGM) has revolutionized the care of type 1 diabetes, and it has also allowed for better troubleshooting in some patients with type 2 diabetes. CGM can provide information on daily glucose fluctuations and how those numbers are affected by everyday activities and stress levels. It also plays an integral part in emerging technology billed as an “artificial pancreas,” partnering with continuous sensing technology to form a closed-loop glycemic control system that includes an insulin pump and controlling algorithms.

Continue reading